Latest News Companion animals

20 May 2026

Unlicensed antiviral products used for the at-home treatment of feline infectious peritonitis contain GS-441524 at significantly different amounts than advertised

OBJECTIVE

To analyze the content of unlicensed GS-441524-like products being used as a largely successful at-home treatment for cats suspected to have FIP. The remdesivir content and pH were also measured.

SAMPLE

127 injectable and oral samples from 30 of the most popular brands of black market producers.

METHODS

Unlicensed GS-441524-like products were procured through donations and tested for GS-441524 and remdesivir content by liquid chromatography with tandem mass spectrometry. A pH meter measured the pH of injectable samples.

RESULTS

Of the 87 injectable formulations, 95% contained more (on average 39% more) GS-441524 than expected based on the producer’s marketed concentrations. The average pH (1.30 pH) was well below the physiologic pH conditions recommended for SC injections. The oral formulations were more variable, with 43% containing more GS-441524 (on average 75% more) than expected and 58% containing less (on average 39% less) than the expected content. There was minimal variability in GS-441524 content between replicate samples in the injectables formulations (measured by coefficient of variation). One injectable and 2 oral samples additionally contained remdesivir.

CLINICAL RELEVANCE

All unlicensed products used for the at-home treatment of FIP that we tested contain GS-441524. The injectables generally contain significantly more drug than advertised at a below-physiologic pH. Unlicensed oral products vary more widely in drug content and suffer from unconventional dosing and labeling. These data should highlight the need for regulation of these products and the development of legal pathways to procure GS-441524.

Read the full article here.

Authors: Alycia M. Kent, Su Guan, Nicole Jacque, Wendy Novicoff, Samantha J. M. Evans

Source: https://avmajournals.avma.org/

Like0

Dislike0

List
Add

Please enter a comment

Name *

Email address *

Comment *

* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.

I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies

Dislike0

EVENTS

Edrapublishing

About Us Authors Contact Us Legal Notes Privacy Search

Top

Unlicensed antiviral products used for the at-home treatment of feline infectious peritonitis contain GS-441524 at significantly different amounts than advertised

Comments

List

Add

Tag

Related Articles

08 April 2026
Effect of oral administration of L-lysine on conjunctivitis caused by feline herpesvirus in cats

Effect of oral administration of L-lysine on conjunctivitis caused by feline herpesvirus in cats

18 February 2026
Focused canine cardiac ultrasound

Focused canine cardiac ultrasound

13 February 2026
Retrospective Study on External Canine Limb Prosthesis used in 24 patients

Retrospective Study on External Canine Limb Prosthesis used in 24 patients

20 August 2025
CATalyst Council Launches Landmark 40,000 Household Pet Ownership Study Focused on Advancing Feline Health

CATalyst Council Launches Landmark 40,000 Household Pet Ownership Study Focused on Advancing Feline Health

28 July 2025
Swine used in the medical university: overview of 20 years of experience

Swine used in the medical university: overview of 20 years of experience

More news

AASV Honors Dr. Robyn Fleck, V92 with the Technical Services/Allied Industry Veterinarian of the Year Award

Chewy Announces Participation in the J.P. Morgan 2026 Global Technology, Media and Communications Conference

Low-Invasive Biomarkers of Canine Mammary Tumours

Occurrence and Risk Factors of Brucellosis in Commercial Cattle Farms from Selected Districts of the Eastern Coast Zone, Tanzania

Hantavirus Outbreak Raises Questions—Here’s How We Can Protect Ourselves

Newsletter

News of interest

Genotyping coronaviruses associated with feline infectious peritonitis

Two TVFS Vets and Two Fire Departments Rescue Horse Stuck in a Bog

The Rescued ‘Rebel’ that Inspired an Unending Scientific Legacy

Dog days: The experience of a clinical trial for a dog and his family

EVENTS